Publications by authors named "S Nanjo"
Background: The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is widely used as a first-line treatment for -mutated non-small cell lung cancer (NSCLC). However, there is no established treatment for osimertinib resistance, so second-generation afatinib is an alternative treatment option. The purpose of this study was to elucidate gene alterations associated with afatinib efficacy and resistance by analyzing cell-free DNA (cfDNA) obtained from patients with -mutated NSCLC.
View Article and Find Full Text PDFBackground/aim: We previously reported the usefulness of detecting aberrant methylation in tumor suppressive microRNAs (miRNAs) in bile and plasma to discriminate pancreaticobiliary cancers from benign pancreaticobiliary diseases. This study analyzed the methylation of miRNAs in pancreatic juice to identify those specific to pancreatic cancer (PC).
Patients And Methods: Pancreatic juice was collected from 20 patients with PC, including eight with intraductal papillary mucinous carcinoma (IPMC), two with low grade-pancreatic intraepithelial neoplasia (LG-PanIN), 32 with LG-intraductal papillary mucinous neoplasm (IPMN), and seven with benign pancreatic lesions.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) can improve cancer treatment but may cause serious side effects, including myocarditis.
- The report discusses two cases of myocarditis that did not respond to corticosteroids, indicating a severe reaction to ICIs.
- Additional treatments like intravenous immunoglobulin and tacrolimus were effective in resolving the myocarditis, suggesting that early use of alternative immunosuppressive therapies should be considered when corticosteroids fail.
Article Synopsis
- - The case involves a 59-year-old man with poorly differentiated lung carcinoma and a rare K601E mutation who showed limited response to the targeted drugs dabrafenib and trametinib after failing chemotherapy and immunotherapy.
- - Although the patient had a significant initial response to the treatment, the tumor's regression lasted only 52 days before progressing, indicating a rapid development of resistance.
- - A follow-up liquid biopsy revealed additional genetic changes associated with resistance, highlighting the complexities of treating K601E-mutant lung carcinoma and the need for improved molecular diagnostics and personalized therapy strategies.
We present the case of a 34-year-old Japanese man with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer and brain metastases. After central nervous system (CNS) disease progression with alecintib and brigatinib, treatment with lorlatinib resulted in a good intracranial response. In this case, we investigated brain penetration ratio of brigatinib using cerebrospinal fluid and paired serum samples, and the ratio was 0.
View Article and Find Full Text PDF